Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
NE NEO NEOGENOMICS INC FY ended Feb 13, 2026 | $17.40 | $2.24B | $2.43B | $727.33M | -$35.54M | -$108.03M | -435.00x | 3.07x | — |
NT NTRA Natera, Inc. FY ended Feb 20, 2026 | $325.17 | $46.87B | $46.70B | $2.31B | -$223.62M | -$208.16M | -213.92x | 20.32x | — |
GH GH Guardant Health, Inc. FY ended Feb 13, 2026 | $163.06 | $21.88B | $22.28B | $982.02M | -$375.16M | -$416.28M | -49.11x | 22.28x | — |
EX EXAS EXACT SCIENCES CORP FY ended Feb 12, 2026 | — | — | — | $3.25B | $37.14M | -$207.95M | — | — | — |
OP OPK OPKO HEALTH, INC. FY ended Jan 30, 2026 | $1.69 | $1.26B | $976.25M | $606.88M | -$136.30M | -$225.68M | -5.63x | 2.08x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/5 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 11.94x | 4/5 | $3.85B | $140.02 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -175.92x | 4/5 | $10.65B | $386.89 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
NE NEO NEOGENOMICS INC FY ended Feb 13, 2026 | $17.40 | $2.24B | $2.43B | $727.33M | -$35.54M | -$108.03M | -435.00x | 3.07x | — |
NT NTRA Natera, Inc. FY ended Feb 20, 2026 | $325.17 | $46.87B | $46.70B | $2.31B | -$223.62M | -$208.16M | -213.92x | 20.32x | — |
GH GH Guardant Health, Inc. FY ended Feb 13, 2026 | $163.06 | $21.88B | $22.28B | $982.02M | -$375.16M | -$416.28M | -49.11x | 22.28x | — |
EX EXAS EXACT SCIENCES CORP FY ended Feb 12, 2026 | — | — | — | $3.25B | $37.14M | -$207.95M | — | — | — |
OP OPK OPKO HEALTH, INC. FY ended Jan 30, 2026 | $1.69 | $1.26B | $976.25M | $606.88M | -$136.30M | -$225.68M | -5.63x | 2.08x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/5 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 11.94x | 4/5 | $3.85B | $140.02 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -175.92x | 4/5 | $10.65B | $386.89 | Peer averages are not economically meaningful for this method. |
